Journal
JOURNAL OF VIROLOGY
Volume 74, Issue 23, Pages 11422-11425Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.74.23.11422-11425.2000
Keywords
-
Categories
Funding
- NCI NIH HHS [CA70071] Funding Source: Medline
- NIAID NIH HHS [AI30731, P01 AI030731] Funding Source: Medline
Ask authors/readers for more resources
We used CD4 lymphocyte clones from herpes simplex virus type 2 (HSV-2) lesions or the cervix and molecular libraries of HSV-2 DNA to define HSV-2 major capsid protein VP5 and glycoprotein E (gE) as T-cell antigens. Responses to eight HSV-2 glycoprotein, tegument, nonstructural, or capsid antigens were compared in 19 donors. Recognition of VP5 and tegument VP22 were similar to that of gB2 and gD2, currently under study as vaccines. These prevalence data suggest that HSV capsid and tegument proteins may also be candidate vaccine antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available